Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)

COMBINATION_PRODUCT2 trials

Sponsors

Respira Therapeutics, Inc.

Conditions

Healthy VolunteerPulmonary Arterial Hypertension

Phase 1

A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234

CompletedNCT05567367

Respira Therapeutics, Inc.Healthy Volunteer

Start: 2018-07-31End: 2019-12-04Updated: 2025-09-22

Phase 2

A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

CompletedNCT05343637

Respira Therapeutics, Inc.Pulmonary Arterial Hypertension

Start: 2019-07-30End: 2020-01-17Updated: 2026-04-06